These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 36123181)

  • 41. Low prevalence of germline CDKN2A and CDK4 mutations in patients with early-onset melanoma.
    Tsao H; Zhang X; Kwitkiwski K; Finkelstein DM; Sober AJ; Haluska FG
    Arch Dermatol; 2000 Sep; 136(9):1118-22. PubMed ID: 10987867
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Alterations of the tumor suppressor genes CDKN2A (p16(INK4a)), p14(ARF), CDKN2B (p15(INK4b)), and CDKN2C (p18(INK4c)) in atypical and anaplastic meningiomas.
    Boström J; Meyer-Puttlitz B; Wolter M; Blaschke B; Weber RG; Lichter P; Ichimura K; Collins VP; Reifenberger G
    Am J Pathol; 2001 Aug; 159(2):661-9. PubMed ID: 11485924
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Chimeras of p14ARF and p16: functional hybrids with the ability to arrest growth.
    Williams RT; Barnhill LM; Kuo HH; Lin WD; Batova A; Yu AL; Diccianni MB
    PLoS One; 2014; 9(2):e88219. PubMed ID: 24505435
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Genomic rearrangements of the CDKN2A locus are infrequent in Italian malignant melanoma families without evidence of CDKN2A/CDK4 point mutations.
    Vignoli M; Scaini MC; Ghiorzo P; Sestini R; Bruno W; Menin C; Gensini F; Piazzini M; Testori A; Manoukian S; Orlando C; D'Andrea E; Bianchi-Scarrà G; Genuardi M
    Melanoma Res; 2008 Dec; 18(6):431-7. PubMed ID: 19011513
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Simultaneous aberrations of single CDKN2A network components and a high Rb phosphorylation status can differentiate subgroups of primary cutaneous B-cell lymphomas.
    Kaune KM; Neumann C; Hallermann C; Haller F; Schön MP; Middel P
    Exp Dermatol; 2011 Apr; 20(4):331-5. PubMed ID: 21410763
    [TBL] [Abstract][Full Text] [Related]  

  • 46. CDKN2A germ-line mutations in individuals with multiple cutaneous melanomas.
    Hashemi J; Platz A; Ueno T; Stierner U; Ringborg U; Hansson J
    Cancer Res; 2000 Dec; 60(24):6864-7. PubMed ID: 11156381
    [TBL] [Abstract][Full Text] [Related]  

  • 47. EZH2 expression in gliomas: Correlation with CDKN2A gene deletion/ p16 loss and MIB-1 proliferation index.
    Purkait S; Sharma V; Jha P; Sharma MC; Suri V; Suri A; Sharma BS; Sarkar C
    Neuropathology; 2015 Oct; 35(5):421-31. PubMed ID: 26096306
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Novel and recurrent p14 mutations in Italian familial melanoma.
    Binni F; Antigoni I; De Simone P; Majore S; Silipo V; Crisi A; Amantea A; Pacchiarini D; Castori M; De Bernardo C; Catricalà C; Grammatico P
    Clin Genet; 2010 Jun; 77(6):581-6. PubMed ID: 20132244
    [TBL] [Abstract][Full Text] [Related]  

  • 49. CDKN2A/p16 genetic test reporting improves early detection intentions and practices in high-risk melanoma families.
    Aspinwall LG; Leaf SL; Dola ER; Kohlmann W; Leachman SA
    Cancer Epidemiol Biomarkers Prev; 2008 Jun; 17(6):1510-9. PubMed ID: 18559569
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Expression and localization of mutant p16 proteins in melanocytic lesions from familial melanoma patients.
    Ghiorzo P; Villaggio B; Sementa AR; Hansson J; Platz A; Nicoló G; Spina B; Canepa M; Palmer JM; Hayward NK; Bianchi-Scarrà G
    Hum Pathol; 2004 Jan; 35(1):25-33. PubMed ID: 14745721
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Contribution of CDKN2A/P16 ( INK4A ), P14 (ARF), CDK4 and BRCA1/2 germline mutations in individuals with suspected genetic predisposition to uveal melanoma.
    Buecher B; Gauthier-Villars M; Desjardins L; Lumbroso-Le Rouic L; Levy C; De Pauw A; Bombled J; Tirapo C; Houdayer C; Bressac-de Paillerets B; Stoppa-Lyonnet D
    Fam Cancer; 2010 Dec; 9(4):663-7. PubMed ID: 20842456
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Analysis of Latvian familial melanoma patients shows novel variants in the noncoding regions of CDKN2A and that the CDK4 mutation R24H is a founder mutation.
    Veinalde R; Ozola A; Azarjana K; Molven A; Akslen LA; Doniņa S; Proboka G; Cēma I; Baginskis A; Pjanova D
    Melanoma Res; 2013 Jun; 23(3):221-6. PubMed ID: 23546221
    [TBL] [Abstract][Full Text] [Related]  

  • 53. CDKN2A and CDK4 variants in Latvian melanoma patients: analysis of a clinic-based population.
    Pjanova D; Engele L; Randerson-Moor JA; Harland M; Bishop DT; Newton Bishop JA; Taylor C; Debniak T; Lubinski J; Kleina R; Heisele O
    Melanoma Res; 2007 Jun; 17(3):185-91. PubMed ID: 17505264
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Molecular genetics of familial cutaneous melanoma.
    Haluska FG; Hodi FS
    J Clin Oncol; 1998 Feb; 16(2):670-82. PubMed ID: 9469357
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Functional impairment of melanoma-associated p16(INK4a) mutants in melanoma cells despite retention of cyclin-dependent kinase 4 binding.
    Becker TM; Rizos H; Kefford RF; Mann GJ
    Clin Cancer Res; 2001 Oct; 7(10):3282-8. PubMed ID: 11595726
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Chromosome 9p21 gene copy number and prognostic significance of p16 in ESFT.
    Brownhill SC; Taylor C; Burchill SA
    Br J Cancer; 2007 Jun; 96(12):1914-23. PubMed ID: 17533400
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Absence of germline epimutation of the CDKN2A gene in familial melanoma.
    van Doorn R; Zoutman WH; Gruis NA
    J Invest Dermatol; 2009 Mar; 129(3):781-4. PubMed ID: 18818678
    [No Abstract]   [Full Text] [Related]  

  • 58. Frequent Genetic Aberrations in the CDK4 Pathway in Acral Melanoma Indicate the Potential for CDK4/6 Inhibitors in Targeted Therapy.
    Kong Y; Sheng X; Wu X; Yan J; Ma M; Yu J; Si L; Chi Z; Cui C; Dai J; Li Y; Yu H; Xu T; Tang H; Tang B; Mao L; Lian B; Wang X; Yan X; Li S; Guo J
    Clin Cancer Res; 2017 Nov; 23(22):6946-6957. PubMed ID: 28830923
    [No Abstract]   [Full Text] [Related]  

  • 59. Frequent alterations in p16/CDKN2A identified by immunohistochemistry and FISH in chordoma.
    Cottone L; Eden N; Usher I; Lombard P; Ye H; Ligammari L; Lindsay D; Brandner S; Pižem J; Pillay N; Tirabosco R; Amary F; Flanagan AM
    J Pathol Clin Res; 2020 Apr; 6(2):113-123. PubMed ID: 31916407
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Bi-allelic Loss of CDKN2A Initiates Melanoma Invasion via BRN2 Activation.
    Zeng H; Jorapur A; Shain AH; Lang UE; Torres R; Zhang Y; McNeal AS; Botton T; Lin J; Donne M; Bastian IN; Yu R; North JP; Pincus L; Ruben BS; Joseph NM; Yeh I; Bastian BC; Judson RL
    Cancer Cell; 2018 Jul; 34(1):56-68.e9. PubMed ID: 29990501
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.